Compare IMXI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | ALLO |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 539.4M |
| IPO Year | 2016 | 2018 |
| Metric | IMXI | ALLO |
|---|---|---|
| Price | $15.94 | $2.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $15.00 | $8.35 |
| AVG Volume (30 Days) | 297.3K | ★ 14.4M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $319,601,000.00 | N/A |
| Revenue This Year | $0.83 | N/A |
| Revenue Next Year | $1.49 | $142,416.42 |
| P/E Ratio | $14.69 | ★ N/A |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $8.58 | $0.86 |
| 52 Week High | $15.94 | $4.46 |
| Indicator | IMXI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 68.17 | 47.02 |
| Support Level | $15.78 | $1.92 |
| Resistance Level | N/A | $2.71 |
| Average True Range (ATR) | 0.04 | 0.35 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 93.75 | 17.43 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.